Abbott Acquires Remaining Rights to Trandolapril from Aventis
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 49 (Table of Contents)
Published: 4 Jul-2004
DOI: 10.3833/pdr.v2004.i49.801 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Abbott Laboratories acquired the remaining manufacturing and marketing rights to trandolapril and its combination drug verapamil from Aventis for a total payment of US$300 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS